Exploring Data Outcomes From the SUNLIGHT Trial
Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.
Read More
Factors Driving 3L Therapeutic Selection for mCRC
Key opinion leaders explore treatment selection for third-line metastatic colorectal cancer patients, examining factors influencing therapy choice with particular focus on comparing fruquintinib to TAS-102 (with or without bevacizumab).
Read More
Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
The colorectal cancer experts offer insights on a patient case and investigate the obstacles faced by patients with metastatic colorectal cancer requiring third-line or later therapy.
Read More
Exploring Toxicities for Second Line Treatments in mCRC
The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.
Read More
Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.
Read More
Clinical Considerations for 2L Treatment Sequencing in mCRC
Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.
Read More
Overview of Molecular Testing and Barriers in mCRC
The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.
Read More
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care
Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
Read More
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd
Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.
Read More
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib
A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
Read More
Assessing HER2 Expression in Metastatic Colorectal Cancer
Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Read More
Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer
Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
Read More
Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy
Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
Read More